Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease.
Identifieur interne : 000666 ( PubMed/Corpus ); précédent : 000665; suivant : 000667Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease.
Auteurs : Natália Pessoa Rocha ; Antônio Lúcio Teixeira ; Paula Luciana Scalzo ; Izabela Guimarães Barbosa ; Mariana Soares De Sousa ; Isabela Boechat Morato ; Erica Leandro Marciano Vieira ; Paulo Pereira Christo ; András Palotás ; Helton José ReisSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2014.
English descriptors
- KwdEn :
- Aged, Biological Markers (blood), Cognition (physiology), Cognition Disorders (blood), Cognition Disorders (complications), Cognition Disorders (diagnosis), Executive Function (physiology), Female, Humans, Male, Middle Aged, Neuropsychological Tests, Parkinson Disease (blood), Parkinson Disease (complications), Parkinson Disease (psychology), Receptors, Tumor Necrosis Factor (blood).
- MESH :
- chemical , blood : Biological Markers, Receptors, Tumor Necrosis Factor.
- blood : Cognition Disorders, Parkinson Disease.
- complications : Cognition Disorders, Parkinson Disease.
- diagnosis : Cognition Disorders.
- physiology : Cognition, Executive Function.
- psychology : Parkinson Disease.
- Aged, Female, Humans, Male, Middle Aged, Neuropsychological Tests.
Abstract
Inflammatory mechanisms have been implicated in a series of neuropsychiatric conditions, including behavioral disturbances, cognitive dysfunction, and affective disorders. Accumulating evidence also strongly suggests their involvement in the pathophysiology of Parkinson's disease (PD). This study aimed to evaluate plasma levels of inflammatory biomarkers, and their association with cognitive performance and other non-motor symptoms of PD. PD patients and control individuals were subjected to various psychometric tests, including the Mini-Mental State Examination (MMSE), Frontal Assessment Battery (FAB), and Beck's Depression Inventory (BDI). Biomarker plasma levels were measured by enzyme-linked immunosorbent assay (ELISA). PD patients exhibited worse performance on MMSE and the programming task of FAB, and presented higher soluble tumor necrosis factor receptor (sTNFR) plasma levels than control individuals. Among PD patients, increased sTNFR1 and sTNFR2 concentrations were associated with poorer cognitive test scores. After multiple linear regression, sTNFR1 and education remained a significant predictor for FAB scores. Our data suggest that PD is associated with a proinflammatory profile, and sTNFRs are putative biomarkers of cognitive performance, with elevated sTNFR1 levels predicting poorer executive functioning in PD patients.
DOI: 10.1002/mds.25752
PubMed: 24301904
Links to Exploration step
pubmed:24301904Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease.</title><author><name sortKey="Rocha, Natalia Pessoa" sort="Rocha, Natalia Pessoa" uniqKey="Rocha N" first="Natália Pessoa" last="Rocha">Natália Pessoa Rocha</name><affiliation><nlm:affiliation>Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Laboratório de Neurofarmacologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Teixeira, Antonio Lucio" sort="Teixeira, Antonio Lucio" uniqKey="Teixeira A" first="Antônio Lúcio" last="Teixeira">Antônio Lúcio Teixeira</name></author><author><name sortKey="Scalzo, Paula Luciana" sort="Scalzo, Paula Luciana" uniqKey="Scalzo P" first="Paula Luciana" last="Scalzo">Paula Luciana Scalzo</name></author><author><name sortKey="Barbosa, Izabela Guimaraes" sort="Barbosa, Izabela Guimaraes" uniqKey="Barbosa I" first="Izabela Guimarães" last="Barbosa">Izabela Guimarães Barbosa</name></author><author><name sortKey="De Sousa, Mariana Soares" sort="De Sousa, Mariana Soares" uniqKey="De Sousa M" first="Mariana Soares" last="De Sousa">Mariana Soares De Sousa</name></author><author><name sortKey="Morato, Isabela Boechat" sort="Morato, Isabela Boechat" uniqKey="Morato I" first="Isabela Boechat" last="Morato">Isabela Boechat Morato</name></author><author><name sortKey="Vieira, Erica Leandro Marciano" sort="Vieira, Erica Leandro Marciano" uniqKey="Vieira E" first="Erica Leandro Marciano" last="Vieira">Erica Leandro Marciano Vieira</name></author><author><name sortKey="Christo, Paulo Pereira" sort="Christo, Paulo Pereira" uniqKey="Christo P" first="Paulo Pereira" last="Christo">Paulo Pereira Christo</name></author><author><name sortKey="Palotas, Andras" sort="Palotas, Andras" uniqKey="Palotas A" first="András" last="Palotás">András Palotás</name></author><author><name sortKey="Reis, Helton Jose" sort="Reis, Helton Jose" uniqKey="Reis H" first="Helton José" last="Reis">Helton José Reis</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24301904</idno><idno type="pmid">24301904</idno><idno type="doi">10.1002/mds.25752</idno><idno type="wicri:Area/PubMed/Corpus">000666</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease.</title><author><name sortKey="Rocha, Natalia Pessoa" sort="Rocha, Natalia Pessoa" uniqKey="Rocha N" first="Natália Pessoa" last="Rocha">Natália Pessoa Rocha</name><affiliation><nlm:affiliation>Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Laboratório de Neurofarmacologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Teixeira, Antonio Lucio" sort="Teixeira, Antonio Lucio" uniqKey="Teixeira A" first="Antônio Lúcio" last="Teixeira">Antônio Lúcio Teixeira</name></author><author><name sortKey="Scalzo, Paula Luciana" sort="Scalzo, Paula Luciana" uniqKey="Scalzo P" first="Paula Luciana" last="Scalzo">Paula Luciana Scalzo</name></author><author><name sortKey="Barbosa, Izabela Guimaraes" sort="Barbosa, Izabela Guimaraes" uniqKey="Barbosa I" first="Izabela Guimarães" last="Barbosa">Izabela Guimarães Barbosa</name></author><author><name sortKey="De Sousa, Mariana Soares" sort="De Sousa, Mariana Soares" uniqKey="De Sousa M" first="Mariana Soares" last="De Sousa">Mariana Soares De Sousa</name></author><author><name sortKey="Morato, Isabela Boechat" sort="Morato, Isabela Boechat" uniqKey="Morato I" first="Isabela Boechat" last="Morato">Isabela Boechat Morato</name></author><author><name sortKey="Vieira, Erica Leandro Marciano" sort="Vieira, Erica Leandro Marciano" uniqKey="Vieira E" first="Erica Leandro Marciano" last="Vieira">Erica Leandro Marciano Vieira</name></author><author><name sortKey="Christo, Paulo Pereira" sort="Christo, Paulo Pereira" uniqKey="Christo P" first="Paulo Pereira" last="Christo">Paulo Pereira Christo</name></author><author><name sortKey="Palotas, Andras" sort="Palotas, Andras" uniqKey="Palotas A" first="András" last="Palotás">András Palotás</name></author><author><name sortKey="Reis, Helton Jose" sort="Reis, Helton Jose" uniqKey="Reis H" first="Helton José" last="Reis">Helton José Reis</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Biological Markers (blood)</term><term>Cognition (physiology)</term><term>Cognition Disorders (blood)</term><term>Cognition Disorders (complications)</term><term>Cognition Disorders (diagnosis)</term><term>Executive Function (physiology)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuropsychological Tests</term><term>Parkinson Disease (blood)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (psychology)</term><term>Receptors, Tumor Necrosis Factor (blood)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biological Markers</term><term>Receptors, Tumor Necrosis Factor</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Cognition Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Cognition Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Cognition Disorders</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Cognition</term><term>Executive Function</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuropsychological Tests</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Inflammatory mechanisms have been implicated in a series of neuropsychiatric conditions, including behavioral disturbances, cognitive dysfunction, and affective disorders. Accumulating evidence also strongly suggests their involvement in the pathophysiology of Parkinson's disease (PD). This study aimed to evaluate plasma levels of inflammatory biomarkers, and their association with cognitive performance and other non-motor symptoms of PD. PD patients and control individuals were subjected to various psychometric tests, including the Mini-Mental State Examination (MMSE), Frontal Assessment Battery (FAB), and Beck's Depression Inventory (BDI). Biomarker plasma levels were measured by enzyme-linked immunosorbent assay (ELISA). PD patients exhibited worse performance on MMSE and the programming task of FAB, and presented higher soluble tumor necrosis factor receptor (sTNFR) plasma levels than control individuals. Among PD patients, increased sTNFR1 and sTNFR2 concentrations were associated with poorer cognitive test scores. After multiple linear regression, sTNFR1 and education remained a significant predictor for FAB scores. Our data suggest that PD is associated with a proinflammatory profile, and sTNFRs are putative biomarkers of cognitive performance, with elevated sTNFR1 levels predicting poorer executive functioning in PD patients.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24301904</PMID><DateCreated><Year>2014</Year><Month>04</Month><Day>04</Day></DateCreated><DateCompleted><Year>2014</Year><Month>12</Month><Day>03</Day></DateCompleted><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>527-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.25752</ELocationID><Abstract><AbstractText>Inflammatory mechanisms have been implicated in a series of neuropsychiatric conditions, including behavioral disturbances, cognitive dysfunction, and affective disorders. Accumulating evidence also strongly suggests their involvement in the pathophysiology of Parkinson's disease (PD). This study aimed to evaluate plasma levels of inflammatory biomarkers, and their association with cognitive performance and other non-motor symptoms of PD. PD patients and control individuals were subjected to various psychometric tests, including the Mini-Mental State Examination (MMSE), Frontal Assessment Battery (FAB), and Beck's Depression Inventory (BDI). Biomarker plasma levels were measured by enzyme-linked immunosorbent assay (ELISA). PD patients exhibited worse performance on MMSE and the programming task of FAB, and presented higher soluble tumor necrosis factor receptor (sTNFR) plasma levels than control individuals. Among PD patients, increased sTNFR1 and sTNFR2 concentrations were associated with poorer cognitive test scores. After multiple linear regression, sTNFR1 and education remained a significant predictor for FAB scores. Our data suggest that PD is associated with a proinflammatory profile, and sTNFRs are putative biomarkers of cognitive performance, with elevated sTNFR1 levels predicting poorer executive functioning in PD patients.</AbstractText><CopyrightInformation>© 2013 International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rocha</LastName><ForeName>Natália Pessoa</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Laboratório de Neurofarmacologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teixeira</LastName><ForeName>Antônio Lúcio</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Scalzo</LastName><ForeName>Paula Luciana</ForeName><Initials>PL</Initials></Author><Author ValidYN="Y"><LastName>Barbosa</LastName><ForeName>Izabela Guimarães</ForeName><Initials>IG</Initials></Author><Author ValidYN="Y"><LastName>de Sousa</LastName><ForeName>Mariana Soares</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Morato</LastName><ForeName>Isabela Boechat</ForeName><Initials>IB</Initials></Author><Author ValidYN="Y"><LastName>Vieira</LastName><ForeName>Erica Leandro Marciano</ForeName><Initials>EL</Initials></Author><Author ValidYN="Y"><LastName>Christo</LastName><ForeName>Paulo Pereira</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Palotás</LastName><ForeName>András</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Reis</LastName><ForeName>Helton José</ForeName><Initials>HJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>12</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018124">Receptors, Tumor Necrosis Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003071">Cognition</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003072">Cognition Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D056344">Executive Function</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009483">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018124">Receptors, Tumor Necrosis Factor</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">cognition</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">non-motor symptoms</Keyword><Keyword MajorTopicYN="N">tumor necrosis factor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2013</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24301904</ArticleId><ArticleId IdType="doi">10.1002/mds.25752</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000666 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000666 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24301904
|texte= Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24301904" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |